

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 03/08/2004

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/072,611	02/08/2002	Brian Leyland-Jones	3298.1001-000	1456
21005 75	5 7590 03/08/2004		EXAMINER	
	BROOK, SMITH & RI	CHEU, CHA	CHEU, CHANGHWA J	
•••	530 VIRGINIA ROAD P.O. BOX 9133		ART UNIT	PAPER NUMBER
CONCORD, M	CONCORD, MA 01742-9133			

Please find below and/or attached an Office communication concerning this application or proceeding.

	****	Application No.	Applicant(s)		
		10/072,611	LEYLAND-JONES, BRIAN		
	Office Action Summary	Examiner	Art Unit		
		Jacob Cheu	1641		
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
THE - Exte - after - If the - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. a period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be tim  within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from to become ABANDONEI  cause the application to become ABANDONEI	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).		
Status					
	Responsive to communication(s) filed on 10 Ju.  This action is <b>FINAL</b> . 2b) This Since this application is in condition for allower closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro			
Dispositi	ion of Claims				
5) 6) 7)	Claim(s) 1-56 is/are pending in the application.  4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed.  Claim(s) is/are rejected.  Claim(s) is/are objected to.  Claim(s) 1-56 are subject to restriction and/or expressions.	vn from consideration.			
Applicati	ion Papers				
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) access applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Examine.	epted or b) objected to by the Eddrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).		
Priority u	ınder 35 U.S.C. § 119				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some color None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.					
Attachmen	t(s)				
2) Notic 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	4) Interview Summary ( Paper No(s)/Mail Dai 5) Notice of Informal Pa 6) Other:			

U.S. Patent and Trademark Office PTOL-326 (Rev. 1-04) ŵ,

## **DETAILED ACTION**

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-30, 51, 54-56, drawn to a method of characterizing a multi-determinant metabolic phenotype, classified in class 436, subclass 6.
  - II. Claims 31-32, 33-37, drawn to a method of using a multi-determinant metabolic phenotype to individualize a treatment regimen, classified in class 436, subclass 15.
  - III. Claims 38-39, drawn to a method of treating an individual, classified in class 435, subclass 7.91.
  - IV. Claims 40-41, drawn to a method of selecting a treatment for an individual corresponding to the individual's metabolic phenotype, classified in class 435, subclass 7.1.
  - V. Claims 42-43, 52-5, drawn to a method of screening a plurality of individuals for participation in a drug treatment trial assessing the therapeutic effect of an agent, classified in class 422, subclass 119.
  - VI. Claims 44-50, drawn to an assay system for detecting the presence of multiple determinant-specific metabolites, classified in class 422, subclass 119.
- 2. Inventions I and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the feature of characterizing a multi-determinant metabolic phenotype, wherein a plurality of phenotypic

Application/Control Number: 10/072,611

Art Unit: 1641

Page 3

determinants are identified as corresponding-to respective metabolic characteristics in invention I, is not required by the claims of other groups. The feature of using a multi-determinant metabolic phenotype to select a drug treatment regimen with a safe and therapeutically effective dose for an individual in invention II, is not required by the claims of other groups. The feature of administering a safe and therapeutically effective dose of at least one compound known for treating said condition, wherein said at least one compound known for treating said condition has a metabolic profile in invention III, is not required by the claims of other groups. The feature of identifying a treatment from a group of candidate treatments that corresponds to said individual's multi-determinant metabolic phenotype in invention IV, is not required by the claims of other groups. The feature of identifying those individuals having a metabolic phenotype characterized as effective for metabolizing said candidate drug treatment in invention V, is not required by the claims of other groups. Each invention group has different operating functions and effects. Thus, inventions I-V are deemed patentably distinct.

- 3. Inventions I-V and IV are related as process and apparatus for its practice. The inventions are distinct if it can be shown that either: (1) the process as claimed can be practiced by another materially different apparatus or by hand, or (2) the apparatus as claimed can be used to practice another and materially different process. (MPEP § 806.05(e)). In this case the assay system of invention IV can be practiced by another materially different process, such as isolation and separation of metabolites from a sample.
- 4. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, the search required for one group is not required for the other, restriction for examination purposes as indicated is proper.
- 5. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 10/072,611

(Alu) Uh

Art Unit: 1641

Page 4

Any inquiry concerning-this communication or earlier communications from the examiner should be directed to Jacob Cheu whose telephone number is 571-282-0814. The examiner can normally be reached on 9:00-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jacob Cheu

Examiner

Art Unit 1641

March 5, 2004

Jankon I.E.

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

03/05/04